Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 4.

Article

Tripathy, D, Tolaney, SM, Seidman, AD et al. (9 more authors) (2019) ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncology, 15 (19). pp. 2211-2225. ISSN 1479-6694

Shaheen, R, Szymanska, K, Basu, B et al. (36 more authors) (2016) Characterizing the morbid genome of ciliopathies. Genome Biology, 17 (1). 242. ISSN 1474-760X

Proceedings Paper

Tripathy, D, Sara, T, Seidman, AD et al. (9 more authors) (2018) ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). In: Cancer Research. 2017 San Antonio Breast Cancer Symposium, 05-09 Dec 2017, San Antonio, Texas, U.S.A.. American Association for Cancer Research .

Tripathy, D, Tolaney, S, Seidman, AD et al. (5 more authors) (2017) Phase 3 study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine. In: Cancer Research. 2016 San Antonio Breast Cancer Symposium, 06 Dec 2016 - 10 Dec 2010, San Antonio, Texas, U.S.A.. American Association for Cancer Research .

This list was generated on Sun Oct 20 17:37:24 2019 BST.